Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme

Journal of Crohn's and Colitis

Volumn 6, Issue 1, 2012, Pages 116-131

  Ferrante, Marc ^a   Karmiris, Konstantinos ^b   Newnham, Evan ^c   Siffledeen, Jesse ^d   Zelinkova, Zuzana ^e   Van Assche, Gert ^a   Lakatos, Peter L ^f   Panés, Julian ^g   Sturm, Andreas ^h   Travis, Simon ^d   Van Der Woude, C Janneke ^e   Reinisch, Walter ⁱ   Colombel, Jean Frédéric ^j   Panaccione, Remo ^k  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Venizelion General Hospital   (Greece)

^c MONASH UNIVERSITY   (Australia)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^g INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j UNIV LILLE   (France)

^k UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

Corticosteroids; Crohn's disease; Disease management; Immunomodulators

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE;

ARTICLE; CANCER RISK; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; IMMUNOMODULATION; INFECTION; INTERVIEW; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; PATIENT SAFETY; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SCORING SYSTEM; TELEPHONE;

ADRENAL CORTEX HORMONES; ATTITUDE OF HEALTH PERSONNEL; CROHN DISEASE; DISEASE MANAGEMENT; HUMANS; IMMUNOLOGIC FACTORS; INTERNATIONALITY; INTERVIEWS AS TOPIC; PHYSICIANS; QUESTIONNAIRES; REMISSION INDUCTION;

EID: 84855936835     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.09.009     Document Type: Article

References (116)

1. Dignass A., van Assche G., Lindsay J.O., Lemann M., Soderholm J., Colombel J.F., Danese S., D'Hoore A., Gassull M., Gomollon F., Hommes D.W., Michetti P., O'Morain C., Oresland T., Windsor A., Stange E.F., Travis S.P. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4:28-62.
2. van Assche G., Dignass A., Panes J., Beaugerie L., Karagiannis J., Allez M., Ochsenkuhn T., Orchard T., Rogler G., Louis E., Kupcinskas L., Mantzaris G., Travis S., Stange E. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010, 4:7-27.
3. Lichtenstein G.R., Hanauer S.B., Sandborn W.J. Management of Crohn's disease in adults. Am J Gastroenterol 2009, 104:465-483.
4. Summers R.W., Switz D.M., Sessions J.T.J., Becktel J.M., Best W.R., Kern F.J., Singleton J.W. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979, 77:847-869.
5. Candy S., Wright J., Gerber M., Adams G., Gerig M., Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995, 37:674-678.
6. Feagan B.G., Rochon J., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., Greenberg G.R., Gillies R., Hopkins M. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995, 332:292-297.
7. Donor breast milk banks: the operation of donor breast milk bank services. National Institute for Health and Clinical Excellence Accessed August 6, 2011, at. http://www.nice.org.uk/guidance/CG93.
8. Feverish illness in children: assessment and initial management in children younger than 5 years. National Institute for Health and Clinical Excellence Accessed August 6, 2011, at. http://www.nice.org.uk/guidance/CG47.
9. Benchimol E.I., Seow C.H., Steinhart A.H., Griffiths A.M. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008, CD006792.
10. Malchow H., Ewe K., Brandes J.W., Goebell H., Ehms H., Sommer H., Jesdinsky H. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984, 86:249-266.
11. Seow C.H., Benchimol E.I., Griffiths A.M., Otley A.R., Steinhart A.H. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008, CD000296.
12. Tromm A., Bunganic I., Tomsova E., Tulassay Z., Lukas M., Kykal J., Batovsky M., Fixa B., Gabalec L., Safadi R., Kramm H.J., Altorjay I., Lohr H., Koutroubakis I., Bar-Meir S., Stimac D., Schaffeler E., Glasmacher C., Dilger K., Mohrbacher R., Greinwald R. Budesonide 9mg is at least as effective as mesalamine 4.5g in patients with mildly to moderately active Crohn's disease. Gastroenterology 2011, 140:425-434.
13. Lundin P.D., Edsbacker S., Bergstrand M., Ejderhamn J., Linander H., Hogberg L., Persson T., Escher J.C., Lindquist B. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. Aliment Pharmacol Ther 2003, 17:85-92.
14. D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., De Vos M., van Deventer S., Stitt L., Donner A., Vermeire S., Van de Mierop F.J., Coche J.C., van der Woude J., Ochsenkuhn T., van Bodegraven A.A., Van Hootegem P.P., Lambrecht G.L., Mana F., Rutgeerts P., Feagan B.G., Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
15. Modigliani R., Mary J.Y., Simon J.F., Cortot A., Soule J.C., Gendre J.P., Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98:811-818.
16. Landi B., Anh T.N., Cortot A., Soule J.C., Rene E., Gendre J.P., Bories P., See A., Metman E.H., Florent C. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992, 102:1647-1653.
17. Lichtenstein G.R., Abreu M.T., Cohen R., Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940-987.
18. Greenberg G.R., Feagan B.G., Martin F., Sutherland L.R., Thomson A.B., Williams C.N., Nilsson L.G., Persson T. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994, 331:836-841.
19. Brignola C., De Simone G., Belloli C., Iannone P., Belluzzi A., Gionchetti P., Campieri M., Barbara L. Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther 1994, 8:465-468.
20. Steinhart A.H., Ewe K., Griffiths A.M., Modigliani R., Thomsen O.O. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2003, CD000301.
21. Benchimol E.I., Seow C.H., Otley A.R., Steinhart A.H. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, CD002913.
22. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Chen D.M., Pritchard M.L., Sandborn W.J. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
23. Stuck A.E., Minder C.E., Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989, 11:954-963.
24. Bernstein C.N., Leslie W.D. Therapy insight: osteoporosis in inflammatory bowel disease-advances and retreats. Nat Clin Pract Gastroenterol Hepatol 2005, 2:232-239.
25. Cosnes J., Cattan S., Blain A., Beaugerie L., Carbonnel F., Parc R., Gendre J.P. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250.
26. Baert F., Moortgat L., van Assche G., Caenepeel P., Vergauwe P., De Vos M., Stokkers P., Hommes D., Rutgeerts P., Vermeire S., D'Haens G. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
27. Froslie K.F., Jahnsen J., Moum B.A., Vatn M.H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
28. Markowitz J., Grancher K., Kohn N., Lesser M., Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000, 119:895-902.
29. Sans M., López-San Román A., Esteve M., Bermejo F., García-Sánchez V., Torres Y. Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology 2011, 140(Suppl. 1):S109.
30. Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J.P., Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
31. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
32. Ardizzone S., Maconi G., Sampietro G.M., Russo A., Radice E., Colombo E., Imbesi V., Molteni M., Danelli P.G., Taschieri A.M., Bianchi P.G. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004, 127:730-740.
33. Hanauer S.B., Korelitz B.I., Rutgeerts P., Peppercorn M.A., Thisted R.A., Cohen R.D., Present D.H. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127:723-729.
34. D'Haens G.R., Vermeire S., van Assche G., Noman M., Aerden I., Van Olmen G., Rutgeerts P. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008, 135:1123-1129.
35. Reinisch W., Angelberger S., Petritsch W., Shonova O., Lukas M., Bar-Meir S., Teml A., Schaeffeler E., Schwab M., Dilger K., Greinwald R., Mueller R., Stange E.F., Herrlinger K.R. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010, 59:752-759.
36. Bernell O., Lapidus A., Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000, 231:38-45.
37. van Assche G., Dignass A., Reinisch W., van der Woude C.J., Sturm A., De Vos M., Guslandi M., Oldenburg B., Dotan I., Marteau P., Ardizzone A., Baumgart D.C., D'Haens G., Gionchetti P., Portela F., Vucelic B., Soderholm J., Escher J., Koletzko S., Kolho K.L., Lukas M., Mottet C., Tilg H., Vermeire S., Carbonnel F., Cole A., Novacek G., Reinshagen M., Tsianos E., Herrlinger K., Oldenburg B., Bouhnik Y., Kiesslich R., Stange E., Travis S., Lindsay J. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010, 4:63-101.
38. Sandborn W.J., Tremaine W.J., Wolf D.C., Targan S.R., Sninsky C.A., Sutherland L.R., Hanauer S.B., McDonald J.W., Feagan B.G., Fedorak R.N., Isaacs K.L., Pike M.G., Mays D.C., Lipsky J.J., Gordon S., Kleoudis C.S., Murdock R.H. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999, 117:527-535.
39. Prefontaine E., Macdonald J.K., Sutherland L.R. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010, CD000545.
40. Prefontaine E., Sutherland L.R., Macdonald J.K., Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, CD000067.
41. Doherty G., Bennett G., Patil S., Cheifetz A., Moss A.C. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009, CD006873.
42. Haines M.L., Ajlouni Y., Irving P.M., Sparrow M.P., Rose R., Gearry R.B., Gibson P.R. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:1301-1307.
43. Treton X., Bouhnik Y., Mary J.Y., Colombel J.F., Duclos B., Soule J.C., Lerebours E., Cosnes J., Lemann M. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009, 7:80-85.
44. Patel V., Macdonald J.K., McDonald J.W., Chande N. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, CD006884.
45. Alfadhli A.A., McDonald J.W., Feagan B.G. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2005, CD003459.
46. Lemann M., Mary J.Y., Colombel J.F., Duclos B., Soule J.C., Lerebours E., Modigliani R., Bouhnik Y. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005, 128:1812-1818.
47. Mary J.Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989, 30:983-989.
48. Daperno M., D'Haens G., van Assche G., Baert F., Bulois P., Maunoury V., Sostegni R., Rocca R., Pera A., Gevers A., Mary J.Y., Colombel J.F., Rutgeerts P. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004, 60:505-512.
49. Colombel J.F., Schwartz D.A., Sandborn W.J., Kamm M.A., D'Haens G., Rutgeerts P., Enns R., Panaccione R., Schreiber S., Li J., Kent J.D., Lomax K.G., Pollack P.F. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009, 58:940-948.
50. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., Kamm M.A., Korzenik J.R., Lashner B.A., Onken J.E., Rachmilewitz D., Rutgeerts P., Wild G., Wolf D.C., Marsters P.A., Travers S.B., Blank M.A., van Deventer S.J. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
51. Clark M., Colombel J.F., Feagan B.C., Fedorak R.N., Hanauer S.B., Kamm M.A., Mayer L., Regueiro C., Rutgeerts P., Sandborn W.J., Sands B.E., Schreiber S., Targan S., Travis S., Vermeire S. American Gastroenterological Association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007, 133:312-339.
52. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
53. Solem C.A., Loftus E.V., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:707-712.
54. Louis E., Vermeire S., Rutgeerts P., De Vos M., Van Gossum A., Pescatore P., Fiasse R., Pelckmans P., Reynaert H., D'Haens G., Malaise M., Belaiche J. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002, 37:818-824.
55. Consigny Y., Modigliani R., Colombel J.F., Dupas J.L., Lemann M., Mary J.Y. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 2006, 12:551-557.
56. Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., Michalsen A., Dobos G.J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008, 103:162-169.
57. Canani R.B., Terrin G., Rapacciuolo L., Miele E., Siani M.C., Puzone C., Cosenza L., Staiano A., Troncone R. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008, 40:547-553.
58. D'Inca R., Dal Pont E., Di Leo V., Benazzato L., Martinato M., Lamboglia F., Oliva L., Sturniolo G.C. Can calprotectin predict relapse risk in inflammatory bowel disease?. Am J Gastroenterol 2008, 103:2007-2014.
59. Wright S., Sanders D.S., Lobo A.J., Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004, 53:1123-1128.
60. Maser E.A., Villela R., Silverberg M.S., Greenberg G.R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
61. Karmiris K., Paintaud G., Noman M., Magdelaine-Beuzelin C., Ferrante M., Degenne D., Claes K., Coopman T., Van Schuerbeek N., van Assche G., Vermeire S., Rutgeerts P. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
62. D'Haens G., Geboes K., Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999, 50:667-671.
63. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., van Assche G., Hoffman I., Van Steen K., Vermeire S., Rutgeerts P. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
64. D'Haens G., Geboes K., Ponette E., Penninckx F., Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997, 112:1475-1481.
65. Kozarek R.A., Patterson D.J., Gelfand M.D., Botoman V.A., Ball T.J., Wilske K.R. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989, 110:353-356.
66. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., Lichtiger S., D'Haens G., Diamond R.H., Broussard D.L., Tang K.L., van der Woude C.J., Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
67. Louis E. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study. Gut 2008, 57(Suppl. 2):A66.
68. Sipponen T., Savilahti E., Kolho K.L., Nuutinen H., Turunen U., Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008, 14:40-46.
69. Pallotta N., Tomei E., Viscido A., Calabrese E., Marcheggiano A., Caprilli R., Corazziari E. Small intestine contrast ultrasonography: an alternative to radiology in the assessment of small bowel disease. Inflamm Bowel Dis 2005, 11:146-153.
70. Rimola J., Rodriguez S., Garcia-Bosch O., Ordas I., Ayala E., Aceituno M., Pellise M., Ayuso C., Ricart E., Donoso L., Panes J. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009, 58:1113-1120.
71. Feagan B., McDonald J.W., Panaccione R., Enns R.A., Berstein C.N., Ponich T.P. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease. Gastroenterology 2008, 135:294-295.
72. van Assche G., Magdelaine-Beuzelin C., D'Haens G., Baert F., Noman M., Vermeire S., Ternant D., Watier H., Paintaud G., Rutgeerts P. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
73. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., Schreiber S., Byczkowski D., Li J., Kent J.D., Pollack P.F. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
74. Sandborn W.J., Feagan B.G., Stoinov S., Honiball P.J., Rutgeerts P., Mason D., Bloomfield R., Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357:228-238.
75. Sokol H., Seksik P., Carrat F., Nion-Larmurier I., Vienne A., Beaugerie L., Cosnes J. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010, 59:1363-1368.
76. Viget N., Vernier-Massouille G., Salmon-Ceron D., Yazdanpanah Y., Colombel J.F. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008, 57:549-558.
77. Beaugerie L., Brousse N., Bouvier A.M., Colombel J.F., Lemann M., Cosnes J., Hebuterne X., Cortot A., Bouhnik Y., Gendre J.P., Simon T., Maynadie M., Hermine O., Faivre J., Carrat F. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374:1617-1625.
78. Rosh J.R., Gross T., Mamula P., Griffiths A., Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?. Inflamm Bowel Dis 2007, 13:1024-1030.
79. Gisbert J.P., Gonzalez-Lama Y., Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007, 102:1518-1527.
80. Dubinsky M.C. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004, 2:731-743.
81. Peyrin-Biroulet L., Deltenre P., de Suray N., Branche J., Sandborn W.J., Colombel J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
82. Siegel C.A., Marden S.M., Persing S.M., Larson R.J., Sands B.E. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881.
83. Wahed M., Louis-Auguste J., Baxter L., Limdi J., Lindsay J., McCartney S., Bloom S. Efficacy of methotrexate in Crohns disease patients previously on thiopurine therapy. Gastroenterology 2008, 134(4 suppl. 1):A661.
84. Garg M., Wilson J., De Cruz P., Brown S., Kamm M., Connell W., Bell S. Methotrexate in thiopurine refractory Crohn's disease-a retrospective cohort study. Gastroenterology 2008, 136(5 suppl. 1):A657.
85. Palaniappan S., Ford A.C., Greer D., Everett S.M., Chalmers D.M., Axon A.T., Hamlin P.J. Mycophenolate mofetil therapy for refractory inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:1488-1492.
86. Hindorf U., Johansson M., Eriksson A., Kvifors E., Almer S.H. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009, 29:654-661.
87. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., van Assche G., Hoffman I., Van Steen K., Vermeire S., Rutgeerts P. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
88. Schreiber S., Panes J., Mason D., Lichtenstein G., Sandborn W. Efficacy and tolerability of certolizumab pegol are sustained over 18 months: data from PRECISE 2 and its extension studies (PRECISE 3 and 4). Gastroenterology 2008, 134(Suppl. 1):A490.
89. Kopylov U., Mantzaris G.J., Katsanos K.H., Reenaers C., Ellul P., Rahier J.F., Israeli E., Lakatos P.L., Fiorino G., Cesarini M., Tsianos E.V., Louis E., Ben-Horin S. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 2011, 33:349-357.
90. Colombel J.F., Sandborn W.J., Rutgeerts P., Kamm M.A., Yu A.P., Wu E.Q., Pollack P.F., Lomax K.G., Chao J., Mulani P.M. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 2009, 104:1170-1179.
91. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., D'Haens G., Li J., Rosenfeld M.R., Kent J.D., Pollack P.F. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829-838.
92. Panaccione R., Sandborn W., D'Haens G., Enns R., Wolf D., Lomax K., Pollack P. Adalimumab maintains long-term remission in moderately to severely active Crohn's disease after infliximab failure: 1-year follow-up of GAIN trial. Gastroenterology 2008, 134(suppl 1):A133-A134.
93. Allez M., Vermeire S., Mozziconacci N., Michetti P., Laharie D., Louis E., Bigard M.A., Hebuterne X., Treton X., Kohn A., Marteau P., Cortot A., Nichita C., van Assche G., Rutgeerts P., Lemann M., Colombel J.F. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010, 31:92-101.
94. Ma C., Panaccione R., Heitman S.J., Devlin S.M., Ghosh S., Kaplan G.G. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther 2009, 30:977-986.
95. D'Haens G., Rutgeerts P. Immunosuppression-associated lymphoma in IBD. Lancet 2009, 374:1572-1573.
96. Kandiel A., Fraser A.G., Korelitz B.I., Brensinger C., Lewis J.D. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121-1125.
97. Armstrong R.G., West J., Card T.R. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010, 105:1604-1609.
98. Shale M., Kanfer E., Panaccione R., Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008, 57:1639-1641.
99. Long M.D., Herfarth H.H., Pipkin C.A., Porter C.Q., Sandler R.S., Kappelman M.D. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010, 8:268-274.
100. Toruner M., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Orenstein R., Sandborn W.J., Colombel J.F., Egan L.J. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
101. Fidder H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., Henckaerts L., van Assche G., Vermeire S., Rutgeerts P. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
102. D'Haens G., Colombel J.F., Hommes D., Panes J., Rutgeerts P.J., Ekborn A., Barai U., van Hoogstraten H., Wiekowski M., Antoni C., et al. Corticosteroids pose an increased risk for serious infection: an interim safety analysis of the ENCORE registry. Gastroenterology 2011, 135(Suppl. 1):A140.
103. Subramanian V., Saxena S., Kang J.Y., Pollok R.C. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol 2008, 103:2373-2381.
104. Ferrante M., D'Hoore A., Vermeire S., Declerck S., Noman M., van Assche G., Hoffman I., Rutgeerts P., Penninckx F. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009, 15:1062-1070.
105. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., Paulus H.E., Mudano A., Pisu M., Elkins-Melton M., Outman R., Allison J.J., Suarez A.M., Bridges S.L., Chatham W.W., Hochberg M., MacLean C., Mikuls T., Moreland L.W., O'Dell J., Turkiewicz A.M., Furst D.E. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
106. Rahier J.F., Ben-Horin S., Chowers Y., Conlon C., De Munter P., D'Haens G., Domenech E., Eliakim R., Eser A., Frater J., Gassull M., Giladi M., Kaser A., Lemann M., Moreels T., Moschen A., Pollok R., Reinisch W., Schunter M., Stange E.F., Tilg H., van Assche G., Viget N., Vucelic B., Walsh A., Weiss G., Yazdanpanah Y., Zabana Y., Travis S.P., Colombel J.F. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91.
107. Wasan S.K., Baker S.E., Skolnik P.R., Farraye F.A. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010, 105:1231-1238.
108. O'Brien J.J., Bayless T.M., Bayless J.A. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991, 101:39-46.
109. Lennard L., Van Loon J.A., Weinshilboum R.M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989, 46:149-154.
110. Sandborn W.J. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001, 48:591-592.
111. Colombel J.F., Ferrari N., Debuysere H., Marteau P., Gendre J.P., Bonaz B., Soule J.C., Modigliani R., Touze Y., Catala P., Libersa C., Broly F. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000, 118:1025-1030.
112. Kaskas B.A., Louis E., Hindorf U., Schaeffeler E., Deflandre J., Graepler F., Schmiegelow K., Gregor M., Zanger U.M., Eichelbaum M., Schwab M. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003, 52:140-142.
113. Vernier-Massouille G., Cosnes J., Lemann M., Marteau P., Reinisch W., Laharie D., Cadiot G., Bouhnik Y., De Vos M., Boureille A., Duclos B., Seksik P., Mary J.Y., Colombel J.F. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007, 56:1404-1409.
114. Dubinsky M.C., Vasiliauskas E.A., Singh H., Abreu M.T., Papadakis K.A., Tran T., Martin P., Vierling J.M., Geller S.A., Targan S.R., Poordad F.F. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003, 125:298-303.
115. Bernstein C.N., Leslie W.D., Leboff M.S. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:795-841.
116. Esrailian E., Spiegel B.M., Targownik L.E., Dubinsky M.C., Targan S.R., Gralnek I.M. Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes. Aliment Pharmacol Ther 2007, 26:1005-1018.